Clinical Trial Search

Primary: 2-year PFS From the Start of Induction Therapy Conditional — 86.6; 90.6; 0.4 percentage of patients

Primary: Participants With Treatment-Emergent (Blinatumomab) Adverse Events — 28; 11; 5; 7 Participants

Primary: Disease-free Survival (DFS) — 77.8; 77.0 Percentage of participants — p=0.276

Primary: Progression-Free Survival Rate at 2 and 5 Years — 78.9; 75.5; 68.0; 66.0 percentage of participants — p=0.6519

Primary: Number of Participants in Complete Remission 6 Months After Randomization — 14; 9 Participants

Primary: R-IPI Index (Revised International Prognostic Index) — 3.4; 32.2; 64.4 percentage of participants

Primary: Event Free Survival — 65; 62 percentage of EFS at 3 years follow-up — p=<0.05

Primary: 1-year Progression-free Survival — 31 Participants

Primary: Number of Participants With Dose-Limiting Toxicities as a Measure of Safety and Tolerability — 0; 0; 0; 1 Participants

Primary: Number of Patients Achieving Complete Response (CR) to the Treatment Upon Successful Stem Cell Mobilization — 10 Participants

Primary: Overall Response Rate — 86.2 percentage of participants

Primary: Overall Response (OR) Rate — 36 Participants

Primary: 2-year Progression-Free Survival (PFS) — 0.76; 0.42 probability

Primary: Toxicity as Assessed by NCI CTCAE v3.0 (Phase I) — 3; 3; 5; 2 Participants

Primary: Maximum Tolerated Dose (MTD) — 100 mg TAK-659

Primary: Progression-free Survival at 1 Year — 77 percentage of participants

Primary: Disease Response (Complete, Complete Unconfirmed, and Partial Responses) After 4 Courses — 47; 8; 14 Participants

Primary: Overall Response (Complete Response + Partial Response) — 216; 94 Participants

Primary: Response Rate = Complete and Partial Response at 12 Weeks. — 5; 3; 2; 15 participants

Primary: Phase 1b: Recommended Phase 2 Dose of Lenalidomide in Combination With Fixed Doses of Ibrutinib and Rituximab in Participants With Relapsed or Refractory Diffuse Large B…

Primary: Disease-free Survival at 1 Year — 0.818; 0.90 years

Primary: Complete Response (CR) Rate — 64.5; 63.5 percentage of participants — p=0.915

Primary: Event-Free Survival (EFS) - Intent-to-Treat (ITT) Population — 49.64; 54.77 Months — p=0.5167

Primary: Event-free Survival After 12 Months — 78 percentage of participants

Primary: Event-free Survival — 76 percentage of patient

Primary: Five-year Progression-free Survival (PFS) Rate in Patients With Newly Diagnosed Limited Stage Diffuse Large B-cell Lymphoma (DLBCL) — 87 percentage of participants

Primary: Number of Participants With Time to Progression (TTP) — 42; 4 Participants

Primary: Percentage of Participants Who Achieved a Complete Response (CR) at the End of Induction Therapy — 54.1; 66.7 percentage of participants

Primary: Number of Participants With Local Control — 61 Participants

Primary: ORR — 13 Participants